Kardigan, Inc. (KARD) has filed for an initial public offering of 23.33 million shares at a price range of $14.00 to $16.00 per share, seeking to raise approximately $350 million at the midpoint. At the midpoint price of $15.00 per share, Kardigan would be valued at approximately $1.3 billion based on 87.67 million shares outstanding following the offering. The company plans to list on the Nasdaq Global Market under the ticker KARD, with J.P. Morgan, Jefferies, Leerink Partners, and TD Cowen serving as lead underwriters.
Kardigan is a clinical-stage biotechnology company focused on developing precision medicines for cardiovascular diseases where no approved therapies currently exist. The company is led by a management team that includes former MyoKardia executives and has assembled a portfolio of three clinical-stage cardiovascular programs targeting large unmet medical needs. Kardigan's strategy combines targeted therapeutics with its proprietary Prolaio platform, which leverages wearable sensors, real-world patient data, and AI-driven analytics to improve clinical trial design and execution.
The company's lead candidate, Danicamtiv, is currently being evaluated in the KINSHIP-DCM Phase 2b/3 trial for genetic dilated cardiomyopathy. Kardigan is also advancing Ataciguat, a soluble guanylate cyclase activator in a Phase 2b trial for moderate calcific aortic valve stenosis, and Tonlamarsen, an antisense oligonucleotide in a Phase 2 trial for the management of acute severe hypertension following hospitalization. All three programs are expected to generate meaningful clinical data during the first half of 2027, creating multiple potential catalysts for investors.
Kardigan's Prolaio platform represents an additional differentiator. The technology integrates wearable sensors with proprietary analytics to collect continuous physiologic data from patients outside traditional clinical settings. Management believes the platform can improve trial efficiency, enhance patient engagement, and support the development of novel digital clinical endpoints that may accelerate drug development.
Financially, Kardigan remains firmly in investment mode as it advances its pipeline. The company reported a net loss of $191.9 million in 2025, compared with $88.7 million in 2024, driven primarily by increased research and development spending. During the first quarter of 2026, Kardigan reported a net loss of $56.1 million. As of March 31, 2026, the company held $81.5 million of cash and cash equivalents and $205.6 million of short-term investments, providing total liquidity of approximately $287.1 million. Following the IPO, pro forma cash and investments are expected to exceed $600 million, which management believes will fund operations into 2028.
Cardiovascular disease remains the leading cause of death globally, yet innovation in the sector has historically lagged other therapeutic areas. Kardigan is attempting to address that gap through a precision medicine approach focused on targeting the underlying drivers of disease rather than treating symptoms alone. With three clinical-stage assets, multiple expected data readouts in 2027, and a well-capitalized balance sheet, Kardigan enters the public markets as one of the larger and more diversified biotechnology IPOs of 2026.
Kardigan, Inc. is expected to IPO on June 18th, 2026.
